Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXER1 | Q8TDS5 | 3/20 | 1.00 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.78 |
| ▸ | MAPT | P10636 | 2/20 | 0.78 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.74 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.74 |
| ▸ | FAAH | O00519 | 3/20 | 0.69 |
| ▸ | PPARG | P37231 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | USP2 | O75604 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.68 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.68 |
| ▸ | FABP4 | P15090 | 1/20 | 0.68 |
| ▸ | HPGD | P15428 | 1/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.68 |
| ▸ | CASP1 | P29466 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1479725 | 1.00 | OXER1 (1.00) | OXER1LTB4R2MAPTALOX5ALDH1A1 | |
| SCHEMBL12970667 | 1.00 | OXER1 (1.00) | OXER1LTB4R2MAPTALOX5ALDH1A1 | |
| SCHEMBL1242004 | 1.00 | OXER1 (1.00) | OXER1LTB4R2MAPTALOX5ALDH1A1 | |
| SCHEMBL6382220 | 1.00 | OXER1 (1.00) | OXER1LTB4R2MAPTALOX5ALDH1A1 | |
| SCHEMBL1479722 | 1.00 | OXER1 (1.00) | OXER1LTB4R2MAPTALOX5ALDH1A1 | |
| SCHEMBL1476445 | 1.00 | OXER1 (1.00) | OXER1LTB4R2MAPTALOX5ALDH1A1 | |
| SCHEMBL16670813 | 1.00 | OXER1 (1.00) | OXER1LTB4R2MAPTALOX5ALDH1A1 | |
| SCHEMBL15902619 | 1.00 | OXER1 (1.00) | OXER1LTB4R2MAPTALOX5ALDH1A1 | |
| SCHEMBL22607964 | 1.00 | OXER1 (1.00) | OXER1LTB4R2MAPTALOX5ALDH1A1 | |
| SCHEMBL21214020 | 1.00 | OXER1 (1.00) | OXER1LTB4R2MAPTALOX5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 367 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107250-A1 | METHODS AND SYSTEMS FOR PROFILING FATTY LIVER DISEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-21 | — | — | WO | claimed |
| CN-122017261-A | Atherosclerosis risk assessment kit and assessment method | 宁波大学附属第一医院(宁波市第一医院) | 2026-05-12 | — | — | CN | claimed |
| EP-4704797-A1 | OXYLIPINS IN THE TREATMENT OF SEBORRHEA | Pierre Fabre Dermo-Cosmétique (FR) | 2026-03-11 | — | — | EP | claimed |
| EP-4687496-A1 | COMPOSITION COMPRISING OXYLIPINS PRESENT IN HUMAN MILK DERIVED SMALL EXTRACELLULAR VESICLES AND ITS USE IN THE PREVENTION AND TREATMENT OF INTESTINAL DISEASES | Fundación Para la Investigación del Hospital Universitario y Politécnico La Fe de la Comunidad Valenciana (ES) | 2026-02-11 | — | — | EP | claimed |
| EP-3452041-B1 | COMPOSITIONS AND METHODS FOR ADMINISTERING PPAR-GAMMA-AGONISTS, SURFACTANT PEPTIDES AND PHOSPHOLIPIDS | LOS ANGELES BIOMEDICAL RES INST HARBOR UCLA MEDICAL CT (US) | 2026-01-14 | — | — | EP | claimed |
| US-20250216407-A1 | LIVER DISEASE TREATMENT AND ASSESSMENT USING OXYLIPINS | INIPHARM, INC. | 2025-07-03 | — | — | US | claimed |
| WO-2025101500-A1 | METHODS FOR GENERATING EXTRACELLULAR VESICLES LOADED WITH RESOLVINS | OHIO STATE INNOVATION FOUNDATION (US) | 2025-05-15 | — | — | WO | claimed |
| US-12274728-B2 | Preparation comprising omega-3 fatty acid salts and extracts of gum resins from Boswellia species | EVONIK OPERATIONS GMBH (DE) | 2025-04-15 | — | — | US | claimed |
| WO-2025038374-A1 | METHODS OF IMPROVING MICROVASCULAR HEALTH | MARS, INCORPORATED (US) | 2025-02-20 | — | — | WO | claimed |
| CN-119069037-B | Detection method of heart failure detection biomarker based on oxidized lipid derivatization and machine learning model | 中国中医科学院医学实验中心 | 2025-02-14 | — | — | CN | claimed |
| WO-2022098757-A1 | SPECIFIC SUBSTRATES AND PRODUCTS OF HSD17B13 AS MARKERS OF LIVER DISEASE AND BIOMARKERS FOR LIVER DISEASE TREATMENT | INIPHARM, INC. (US) | 2022-05-12 | — | — | WO | claimed |
| CN-112697889-B | Application of serum metabolism marker and detection kit | 中国科学院大连化学物理研究所 | 2022-03-08 | — | — | CN | claimed |
| WO-2022032230-A1 | INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR TREATING NEURODEGENERATION | CASE WESTERN RESERVE UNIVERSITY (US) | 2022-02-10 | — | — | WO | claimed |
| WO-2005102309-A2 | IN VIVO RELEASE OF ENDOGENOUS ANTI-MICROBIAL MEDIATORS BY LEUKOTRIENE B4 (LTB4) ADMINISTRATION | LTB4 SWEDEN AB (SE) | 2005-11-03 | — | — | WO | claimed |
| US-20050239889-A1 | In vivo release of endogenous anti-microbial mediators by leukotriene B4 (LTB4) administration | GOSSELIN JEAN | 2005-10-27 | — | — | US | claimed |
| US-20040132820-A1 | Agents with leukotriene B4-like antiviral (DNA) and anti-neoplastic activities | GOSSELIN JEAN (CA) | 2004-07-08 | — | — | US | claimed |
| US-6093741-A | ANTI-NEOPLASTIC AGENT IN THE PROPHYLAXIS AND TREATMENT OF CANCERS INDUCED BY TUMOR VIRUSES AND IN OTHER NEOPLASIC DISEASES | VIROCELL INC. (CA) | 2000-07-25 | — | — | US | claimed |
| JP-2000505435-A | — | — | 2000-05-09 | — | — | JP | claimed |
| EP-0881900-A1 | USE OF LEUKOTRIENE B 4? OR ITS ANALOGUES AS ANTIVIRAL AND ANTINEOPLASTIC AGENTS | Virocell Inc. (CA) | 1998-12-09 | — | — | EP | claimed |
| WO-1997029751-A1 | USE OF LEUKOTRIENE B4 OR ITS ANALOGUES AS ANTIVIRAL AND ANTINEOPLASTIC AGENTS | VIROCELL INC. (CA) | 1997-08-21 | — | — | WO | claimed |